Drug Profile
Research programme: anticancer antibodies - Cancer Research UK/AstraZeneca
Alternative Names: 264RAD; Cancer therapeutics - Cancer Research UK/AstraZenecaLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Cancer Research UK; MedImmune
- Developer AstraZeneca; Cancer Research UK
- Class Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Pancreatic cancer
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for research development in Pancreatic-cancer in United Kingdom (Parenteral)
- 15 Sep 2020 Early research development is ongoing in United Kingdom for Pancreatic cancer (Cancer Research UK pipeline, September 2020)
- 28 Aug 2020 No recent reports of development identified for research development in Pancreatic-cancer in United Kingdom (Parenteral)